Search clinical trials for: Claudin 18.2 CAR-T

Total 968 results

Second Affiliated Hospital, School of Medicine,...

Recruiting

Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma

Relapsed and Refractory B-cell Lymphoma

China
Fondazione Italiana Linfomi - ETS
Kite, A Gilead Company

Recruiting

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Non-hodgkin Lymphoma,B Cell

Italy
Hrain Biotechnology Co., Ltd.
Shanghai Zhongshan Hospital

Recruiting

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

B-cell Non-Hodgkin's Lymphoma

China
Medical College of Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Central Nervous System Lymphoma | Mantle Cell Lymphoma (MCL) | Non Hodgkin Lymphoma (NHL)

United States
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma (CD19-CARNK/T)

Mantle Cell Lymphoma (MCL) | Primary Mediastinal B-cell Lymphoma (PMBCL) | Diffuse Large B Cell Lymphoma( DLBCL)
Zhongda Hospital

Recruiting

Clinical Study of TCR-like CAR-T Cell Targeted MSLN in the Treatment of Ovarian Cancer

Safety and Efficacy of TCR-like CAR-T

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

Multiple Myeloma

China
Stephan Grupp MD PhD
Children's Hospital of Philadelphia; University of Pennsylvania; Tmunity Therapeutics

Recruiting

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma (GPC2)

Refractory Neuroblastoma | High-risk Neuroblastoma | Relapsed Neuroblastoma

United States
Shenzhen University General Hospital

Recruiting

Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Shenzhen University General Hospital

Recruiting

Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T

Advanced Pancreatic Carcinoma | Advanced Gastric Carcinoma

China
University College, London

Recruiting

CAR T Cells to Target GD2 for DMG (CARMIGO)

Diffuse Midline Glioma, H3 K27M-Mutant

United Kingdom
Beijing Immunochina Medical Science & Technology...

Recruiting

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Leukemia

China
Beijing Immunochina Medical Science & Technology...

Recruiting

Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma

Multiple Myeloma

China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou Medical University

Recruiting

Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer

Immunotherapy

China
Chinese PLA General Hospital

Recruiting

CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALL

CD19+ Relapse/Refractory B-ALL

China
Shenzhen University General Hospital

Recruiting

CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer (CAR-T)

Advanced Pancreatic Carcinoma

China
University of Colorado, Denver

Recruiting

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

Non-Hodgkin Lymphoma

United States
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma Cell

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei Hospital

Recruiting

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Lymphoma | Leukemia | Multiple Myeloma of Bone (Diagnosis)

China
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia

B-cell Acute Lymphocytic Leukemia

China
Caribou Biosciences, Inc.

Enrolling by invitation

Long-Term Follow-up Study (LTFS)

Lymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Hematologic Malignancy | Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Acute Myeloid Leukemia | Relapsed Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin's Lymphoma

United States
Marcela V. Maus, M.D.,Ph.D.

Completed

CAR-37 T Cells In Hematologic Malignancies

Lymphoma | Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Leukemia | Lymphoma, T-Cell | Hematologic Malignancy

United States
Memorial Sloan Kettering Cancer Center

Withdrawn

A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

Lymphoma | Lymphoma, B-Cell | Leukemia

United States
Sheba Medical Center

Unknown

T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies

Acute Lymphoblastic Leukemia, B-precursor | Non-Hodgkin Lymphoma, B-cell

Israel
Fuda Cancer Hospital, Guangzhou

Withdrawn

CAR-T Cell Immunotherapy for HCC Targeting GPC3

CAR-T Cell Immunotherapy | GPC3 Positive Hepatocellular Carcinoma

China
The First Affiliated Hospital of Nanchang University

Unknown

Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas

Acute Lymphoblastic Leukemia ,Lymphomas

China
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.; Union Stem cell & gene engineering Co.LTD

Completed

CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, Adult B-Cell | Acute Lymphoblastic Leukaemia Recurrent

China
Tianjin Mycure Medical Technology Co., Ltd

Unknown

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

B-cell Acute Lymphoblastic Leukemia

China
Southwest Hospital, China

Unknown

A Clinical Research of CAR T Cells Targeting CEA Positive Cancer

Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Unknown

CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma Progression

China
Instituto de Investigación Biomédica de Salamanca
Carlos III Health Institute

Recruiting

Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment

Diffuse Large B Cell Lymphoma

Spain
Instituto de Investigación Biomédica de Salamanca
Spanish Clinical Research Network - SCReN; Fundación Canaria de Investigación... and other collaborators

Recruiting

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19)

B-cell Lymphoma Recurrent | Refractory B-Cell Lymphoma

Spain
Zhu Xiaofan

Recruiting

CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

B Lymphoblastic Lymphoma | B Lymphocytic Leukemia

China
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma

Acute T-lymphoblastic Leukemia | Acute T-lymphoblastic Lymphoma

China
Centre Henri Becquerel

Not yet recruiting

Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells (RT-CAR)

Diffuse Large B Cell Lymphoma

France
Beijing Friendship Hospital
Beijing Boren Hospital

Not yet recruiting

Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell Histiocytosis

Langerhans Cell Histiocytosis

China
Zhejiang University

Not yet recruiting

Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML

AML

China
Ying Wang

Recruiting

CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

Hematological Malignancies

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer

EGFR/ B7H3-positive Advanced Lung Cancer | EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies

AML

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies

AML

China
The First Affiliated Hospital of Soochow University
CARsgen Therapeutics Co., Ltd.

Recruiting

A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

China
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; The Affiliated... and other collaborators

Recruiting

Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Leukemia | Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia, B-cell

China
Chongqing Precision Biotech Co., Ltd

Recruiting

CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

Refractory T-Cell Lymphoma | T Cell Lymphoma in Relapse

China
Beijing Tsinghua Chang Gung Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Suspended

GPC3-CAR-T Cells for the Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Fuda Cancer Hospital, Guangzhou

Withdrawn

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

GD2 Positive Glioma | CAR-T Cell Immunotherapy

China
Xin Wang

Unknown

The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma

Relapsed or Refractory B-cell Lymphomas

China

Search clinical trials for: Claudin 18.2 CAR-T

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations